Important tools to build understanding and support for bioscience issues.

Each testimony, brief or letter is formalized and approved by the our Government Affairs Committee and Board of Directors.

2019 Legislative Session Report

February 4, 2019

Democrats in the Connecticut General Assembly announced joint priorities for the 2019 legislative session. The legislative package focuses on establishing a paid family and medical leave program, raising the minimum wage, investing in job training and the state’s workforce pipeline, supporting small businesses, making prescription drugs more affordable, creating a Green New Deal for Connecticut and increasing access to the ballot box.

View


Legislature’s Bioscience Caucus, Industry Partners Announce Strategic Plan

January 31, 2019

January 30th, the co-Chairs of the Legislature’s Bioscience Caucus met with their main industry counterpart, BioCT, to discuss the strategic plan developed since the last legislative session, and announce specific goals for the coming session. Alongside co-Chairs State Senator Tony Hwang (R-28), State Senator Christine Cohen (D-12), State Rep. Stephen Harding (R-107), and Rep. Jonathan Steinberg (D-136) was BioCT President & CEO Dawn Hocevar and Dr. Mark Adams, Director of Microbial Genomic Services at Jackson Labs.

View   Video


2018 Legislative Session Report

February 7, 2018

We are happy to provide you with the 2018 End of Session Report. The Connecticut General Assembly adjourned sine die after making adjustments to close the projected $265 million deficit in fiscal year 2019 in a bipartisan agreement. Additionally, conversations continue as to whether the General Assembly will return for a special session to address sports wagering as a result of the recent Supreme Court case striking down a 26-year federal law that barred all but four states from that practice.

View


An Act Concerning a Study of the Bioscience Industry

March 9, 2017

For the foregoing reasons, BioCT urges this Committee to progress S.B. No. 960. It is important for the State to conduct the study, particularly if it is to remain competitive in biotechnology. The Bill is therefore in the best interest of the State’s biotechnology and pharmaceutical industries, and for developing new and innovative medicines and therapies for our people.

View


An Act Concerning the Development of Evaluative Metrics for Bioscience Investments in the State

March 9, 2017

For the foregoing reasons, BioCT urges this Committee to progress S.B. No. 962. It is important to pursue the development of evaluative metrics for bioscience investments in the Connecticut, particularly if it is to remain competitive in biotechnology. The Bill is therefore in the best interest of the State’s biotechnology and pharmaceutical industries, and for developing new and innovative medicines and therapies for our people.

View

The Importance of Sustained Support for Bioscience in Connecticut

January 23, 2017

The bioscience industry represents a significant share of the State economy and has potential for substantial growth in the coming decade. We hope that the General Assembly will sustain that commitment to growing the bioscience industry through support for research and tax incentives, particularly in view of the current economic climate and the budgetary challenges facing the state.

View


An Act Concerning Biological Products

March 8, 2016

For the foregoing reasons, CURE urges this Committee to progress S.B. No. 313. It is in the best interest of patients, the State’s biotechnology and pharmaceutical industries, and the public at large. The legislation will update Connecticut’s Pharmacy Practice Act to establish a clear substitution process for FDA approved interchangeable biological medicines. Patients here in Connecticut will thereby be provided treatment options, which have already been addressed through legislation in many other states, which would otherwise not be available to them here in this State.

View


An Act Concerning the Right to Try Experimental Drugs

February 24, 2016

For the foregoing reasons, H.B. No. 5270 is not in the best interest of critically ill patients, the State’s thriving biotechnology and pharmaceutical industries, and the public at large. While this legislation is well-intended, it neglects to consider serious challenges associated with providing access to experimental medicines.

View


Seeing Through Drug Pricing ‘Transparency’ Legislation

Legislative “transparency” initiatives typically describe efforts to give consumers information they can use to make informed decisions. But drug pricing transparency bills are not that kind of legislation. Here, “transparency” refers to the government’s effort to force drug manufacturers to disclose proprietary and competitively sensitive business information in an attempt to coerce companies into restricting the price of their products to artificial, government-set thresholds.

View


Your Comprehensive Guide to the Drug Cost Ecosystem

The Biotechnology Innovation Organization (BIO) today launched DrugCostFacts.org, a new interactive web tool designed to help healthcare stakeholders gain a better understanding of the true facts surrounding drug costs, spending and value.

View


To access archived materials, please send an inquiry to BioCT@bioct.org.